Lyme disease vaccine shows safety in children aged 5-17 in phase 3 trial
A four-dose series of an investigational Lyme disease vaccine demonstrated safety and tolerability in children and teens aged 5-17 years in phase 3 randomized controlled trial results presented at the American Academy of Pediatrics 2026 National Conference. The development comes as drugmakers race to create effective defenses against Lyme disease amid intensifying tick seasons.